37 related articles for article (PubMed ID: 35680629)
1. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
[TBL] [Abstract][Full Text] [Related]
3. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
Wang Y; Shi Q; Shi ZY; Tian S; Zhang MC; Shen R; Fu D; Dong L; Yi HM; Ouyang BS; Mu RJ; Cheng S; Wang L; Xu PP; Zhao WL
Blood Adv; 2024 Apr; 8(7):1587-1599. PubMed ID: 38170757
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization and genetic subclassification comparison of diffuse large B-cell lymphoma (DLBCL) - real-life experience with 74 cases.
Ivanova VS; Vela V; Dirnhofer S; Dobbie M; Stenner F; Knoblich J; Tzankov A; Menter T
Pathobiology; 2023 Dec; ():. PubMed ID: 38128501
[TBL] [Abstract][Full Text] [Related]
5. The Genetic Profile of Large B-Cell Lymphomas Presenting in the Ocular Adnexa.
Vest SD; Eriksen PRG; de Groot FA; de Groen RAL; Kleij AHR; Kirkegaard MK; Kamper P; Rasmussen PK; von Buchwald C; de Nully Brown P; Kiilgaard JF; Vermaat JSP; Heegaard S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542066
[TBL] [Abstract][Full Text] [Related]
6. MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B-cell lymphoma patients.
Wang Y; Liu D; Zhang X; Zhang M; Li S; Feng X; Dong M; Ma S; Qian S; Wang Z; Zhang Y; Wang P; Mei S; Chen Q
Cancer Med; 2023 Sep; 12(18):18568-18577. PubMed ID: 37641492
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Features and Prognostic Factors of Patients with Primary Cutaneous Lymphoma].
Rexidan NM; Wang PL; Zhang ZR; Chen D; Cui ZY; Yang JB; Jiang TY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1379-1384. PubMed ID: 37846688
[TBL] [Abstract][Full Text] [Related]
8. Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
Zhu ML; Drill E; Joffe E; Salles G; Delgado AR; Zelenetz A; Palomba ML; Arcila M; Dogan A
Haematologica; 2024 Mar; ():. PubMed ID: 38497151
[TBL] [Abstract][Full Text] [Related]
9. Genotyping on circulating tumor DNA improves mutation detection rate in high-risk diffuse large B-cell lymphoma.
Xia Y; Wang L; Liang J; Shen H; Wu J; Yin H; Li Y; Zhu H; Li J; Xu W
Genes Dis; 2024 Jul; 11(4):101116. PubMed ID: 38515934
[No Abstract] [Full Text] [Related]
10. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
[TBL] [Abstract][Full Text] [Related]
12. Biological heterogeneity in diffuse large B-cell lymphoma.
Hilton LK; Scott DW; Morin RD
Semin Hematol; 2023 Nov; 60(5):267-276. PubMed ID: 38151380
[TBL] [Abstract][Full Text] [Related]
13. [Distribution and prognostic value of LymphGen genotyping in patients with diffuse large B-cell lymphoma].
Zhang F; Renaguli A; Qi XL; Kou Z; Zhai SS; Tan W; Muhebaier A; Nie YL; Li Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):305-310. PubMed ID: 35680629
[No Abstract] [Full Text] [Related]
14. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
Xu-Monette ZY; Wei L; Fang X; Au Q; Nunns H; Nagy M; Tzankov A; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Sun X; Han X; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Albitar M; You H; Young KH
Clin Cancer Res; 2022 Mar; 28(5):972-983. PubMed ID: 34980601
[TBL] [Abstract][Full Text] [Related]
15. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
